| ZBH |
Report |
Q2 2026 Total Net Sales |
IN-LINE |
pred ~$2.14B vs. cons $2.13B |
MEDIUM |
| ZBH |
Report |
Q2 2026 Adjusted EPS |
BEAT |
pred ~$2.05 vs. cons $2.01 |
MEDIUM |
| ZBH |
Report |
Q2 2026 U.S. Knees Revenue Growth YoY |
MISS |
pred ~1.0% vs. cons 1.9% |
MEDIUM |
| ZBH |
Guide |
FY2026 Organic Constant-Currency Revenue Growth Guidance |
UNCHANGED |
guide ~2% (midpoint of reaffirmed 1%-3% range) vs. cons ~2% (FY2026) |
HIGH |
| ZBH |
Guide |
FY2026 Adjusted EPS Guidance |
UNCHANGED |
guide ~$8.48 (midpoint of $8.40-$8.55) vs. cons ~$8.48 (FY2026) |
MEDIUM |
| ZBH |
Guide |
Q3 2026 Operating Margin Sequential Improvement vs. Q2 |
UNCHANGED |
guide ~+50bps sequential vs. cons ~+50bps expected (Q3 2026) |
MEDIUM |
| ZBH |
Return |
Day-1 residual (stock − beta × S&P 500) |
-1.8% |
— |
MEDIUM |
| ZBH |
Return |
5-day cumulative residual |
-3.2% (FADE) |
Even with an EPS beat, the explicit -200bps Q2 margin guide, reaffirmed (not raised) FY organic growth range, fading tariff pull-forward benefit, ongoing CFO search, and softer U.S. knee/international trends leave sell-side models with more downside skew for H2 than upside. Analysts likely trim out-quarter margin/EPS estimates to reflect the guided Q3 sequential-only recovery and Section 232 tariff risk, causing initial relief (if EPS beats) to fade over the following days as estimate revisions catch down, consistent with the stock's recent run-up into the print raising the bar for sustained follow-through. |
LOW |